Clinical Cancer Research, Vol 2, Issue 12 2015-2022, Copyright © 1996 by American Association for Cancer Research

ARTICLES

bcl-2 and p53 expression in resectable pancreatic adenocarcinomas: association with clinical outcome

FA Sinicrope, DB Evans, SD Leach, KR Cleary, CJ Fenoglio, JJ Lee and JL Abbruzzese
Departments of Gastrointestinal Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.

The bcl-2 proto-oncogene and the p53 tumor suppressor gene are important determinants of tumor cell susceptibility to apoptosis. bcl-2 and mutant p53 proteins inhibit apoptosis in vitro and can provide prognostic information in certain tumor types. We analyzed bcl-2 and p53 expression in archival pancreatic (n = 35) and ampullary (n = 6) adenocarcinomas, resected for cure, and their relationship to overall survival. Patients were treated with 5-fluorouracil and irradiation either pre- (n = 21) or postoperatively (n = 15); 5 patients received surgery alone. Using specific monoclonal antibodies, cytoplasmic bcl-2 and nuclear p53 proteins were detected in 22 of 40 (55%) and 20 of 37 (54%) tumors, respectively. No relationship was found between bcl-2 and p53 expression. Neither bcl-2 nor p53 correlated with histological response to preoperative chemoradiation. Lymph node involvement predicted poor overall survival (P = 0.02). A trend toward improved survival was seen in well-differentiated (P = 0.08) tumors and in those with increased bcl-2 expression (P = 0.06). p53 expression was not related to clinical outcome. In a multivariate analysis, nodal status was the single most important predictor of overall survival. Of note, the combined variable of bcl-2 expression and histological grade was a stronger prognostic variable than nodal status alone. Unlike nodal status, these features can potentially be evaluated in preoperative biopsy specimens.

This article has been cited by other articles:

				C. J. Bruns, C. C. Solorzano, M. T. Harbison, S. Ozawa, R. Tsan, D. Fan, J. Abbruzzese, P. Traxler, E. Buchdunger, R. Radinsky, et al. Blockade of the Epidermal Growth Factor Receptor Signaling by a Novel Tyrosine Kinase Inhibitor Leads to Apoptosis of Endothelial Cells and Therapy of Human Pancreatic Carcinoma Cancer Res., June 1, 2000; 60(11): 2926 - 2935. [Abstract] [Full Text] [PDF]

				H. Kuniyasu, L. M. Ellis, D. B. Evans, J. L. Abbruzzese, C. J. Fenoglio, C. D. Bucana, K. R. Cleary, E. Tahara, and I. J. Fidler Relative Expression of E-Cadherin and Type IV Collagenase Genes Predicts Disease Outcome in Patients with Resectable Pancreatic Carcinoma Clin. Cancer Res., January 1, 1999; 5(1): 25 - 33. [Abstract] [Full Text] [PDF]

				Y. Soini, P. Paakko, and V-P. Lehto Histopathological Evaluation of Apoptosis in Cancer Am. J. Pathol., October 1, 1998; 153(4): 1041 - 1053. [Full Text] [PDF]

				N. Liu, T. Furukawa, M. Kobari, and M.-S. Tsao Comparative Phenotypic Studies of Duct Epithelial Cell Lines Derived from Normal Human Pancreas and Pancreatic Carcinoma Am. J. Pathol., July 1, 1998; 153(1): 263 - 269. [Abstract] [Full Text] [PDF]